Jonathan Wolleben
Stock Analyst at JMP Securities
(4.27)
# 388
Out of 4,945 analysts
213
Total ratings
51.15%
Success rate
15.03%
Average return
Main Sectors:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHVS Pharvaris | Maintains: Market Outperform | $55 → $52 | $22.99 | +126.19% | 12 | Aug 13, 2025 | |
| ATXS Astria Therapeutics | Maintains: Market Outperform | $25 → $26 | $6.75 | +285.19% | 3 | Aug 13, 2025 | |
| QNCX Quince Therapeutics | Maintains: Market Outperform | $9 → $8 | $1.68 | +376.19% | 2 | Aug 12, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Market Outperform | $90 → $86 | $29.69 | +189.66% | 15 | Aug 11, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Market Outperform | $67 → $69 | $55.03 | +25.40% | 12 | Aug 7, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Market Outperform | $79 → $81 | $64.78 | +25.04% | 11 | Aug 7, 2025 | |
| GPCR Structure Therapeutics | Maintains: Market Outperform | $89 → $87 | $18.53 | +369.51% | 10 | Aug 7, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Market Outperform | $130 → $135 | $96.49 | +39.91% | 4 | Aug 6, 2025 | |
| ALT Altimmune | Maintains: Market Outperform | $25 → $15 | $3.68 | +307.61% | 13 | Jul 10, 2025 | |
| KALV KalVista Pharmaceuticals | Maintains: Market Outperform | $19 → $27 | $12.95 | +108.49% | 4 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $2.02 | +296.04% | 8 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $9.82 | +113.85% | 15 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $15 | $3.27 | +358.72% | 3 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $7.03 | +170.27% | 9 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $5 | $0.45 | +1,013.83% | 11 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $443 | $371.37 | +19.29% | 12 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $38 | $13.21 | +187.66% | 1 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $22 → $19 | $12.65 | +50.20% | 17 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $18 | $8.45 | +113.02% | 8 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $3.01 | +199.00% | 8 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $50 | $45.26 | +10.47% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $90 | $87.97 | +2.31% | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $124.64 | - | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Accumulate | $420 → $485 | $698.50 | -30.57% | 1 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $48 → $32 | $8.67 | +269.09% | 8 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $25 | $4.26 | +486.85% | 11 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $0.55 | +1,365.20% | 11 | Apr 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $24 | $32.25 | -25.58% | 1 | May 12, 2023 |
Pharvaris
Aug 13, 2025
Maintains: Market Outperform
Price Target: $55 → $52
Current: $22.99
Upside: +126.19%
Astria Therapeutics
Aug 13, 2025
Maintains: Market Outperform
Price Target: $25 → $26
Current: $6.75
Upside: +285.19%
Quince Therapeutics
Aug 12, 2025
Maintains: Market Outperform
Price Target: $9 → $8
Current: $1.68
Upside: +376.19%
Crinetics Pharmaceuticals
Aug 11, 2025
Maintains: Market Outperform
Price Target: $90 → $86
Current: $29.69
Upside: +189.66%
Protagonist Therapeutics
Aug 7, 2025
Maintains: Market Outperform
Price Target: $67 → $69
Current: $55.03
Upside: +25.40%
Mirum Pharmaceuticals
Aug 7, 2025
Maintains: Market Outperform
Price Target: $79 → $81
Current: $64.78
Upside: +25.04%
Structure Therapeutics
Aug 7, 2025
Maintains: Market Outperform
Price Target: $89 → $87
Current: $18.53
Upside: +369.51%
Rhythm Pharmaceuticals
Aug 6, 2025
Maintains: Market Outperform
Price Target: $130 → $135
Current: $96.49
Upside: +39.91%
Altimmune
Jul 10, 2025
Maintains: Market Outperform
Price Target: $25 → $15
Current: $3.68
Upside: +307.61%
KalVista Pharmaceuticals
Jul 8, 2025
Maintains: Market Outperform
Price Target: $19 → $27
Current: $12.95
Upside: +108.49%
Jun 27, 2025
Reiterates: Market Outperform
Price Target: $8
Current: $2.02
Upside: +296.04%
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $21
Current: $9.82
Upside: +113.85%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $3.27
Upside: +358.72%
May 23, 2025
Reiterates: Market Outperform
Price Target: $19
Current: $7.03
Upside: +170.27%
May 16, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $0.45
Upside: +1,013.83%
Apr 24, 2025
Reiterates: Market Outperform
Price Target: $443
Current: $371.37
Upside: +19.29%
Apr 10, 2025
Initiates: Market Outperform
Price Target: $38
Current: $13.21
Upside: +187.66%
Mar 4, 2025
Maintains: Market Outperform
Price Target: $22 → $19
Current: $12.65
Upside: +50.20%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $8.45
Upside: +113.02%
Dec 19, 2024
Reiterates: Market Outperform
Price Target: $9
Current: $3.01
Upside: +199.00%
Dec 18, 2024
Maintains: Market Outperform
Price Target: $55 → $50
Current: $45.26
Upside: +10.47%
Dec 16, 2024
Reiterates: Market Outperform
Price Target: $90
Current: $87.97
Upside: +2.31%
Dec 16, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $124.64
Upside: -
Nov 13, 2024
Downgrades: Accumulate
Price Target: $420 → $485
Current: $698.50
Upside: -30.57%
Aug 15, 2024
Maintains: Market Outperform
Price Target: $48 → $32
Current: $8.67
Upside: +269.09%
May 31, 2024
Reiterates: Market Outperform
Price Target: $25
Current: $4.26
Upside: +486.85%
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $8
Current: $0.55
Upside: +1,365.20%
May 12, 2023
Maintains: Outperform
Price Target: $25 → $24
Current: $32.25
Upside: -25.58%